Ph3 BMS-986365 study of comparing a second androgen receptor pathway inhibitor in mCRPC
Phase III Clinical Trial
A Phase 3 Two-part Randomized Open-label Adaptive Study Comparing BMS-986365 versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI) in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (CA071-1000)